{"analyses":[{"ciLowerLimit":"0.635","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.013","estimateComment":"A hazard ratio \\< 1.0 indicates a lower average event rate and a longer overall survival time for denosumab relative to placebo.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Analysis of OS was conditional on the outcome of DFS due to hierarchical testing strategy, therefore p-value not reported.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.802"}],"classes":[{"categories":[{"measurements":[{"comment":"Not reached due to the low number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not reached due to the low number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1709"},{"groupId":"OG001","value":"1711"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive the matching placebo subcutaneously (SC) once every 6 months (Q6M) in the double-blind phase. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.","id":"OG000","title":"Placebo"},{"description":"Participants randomized to receive 60 mg denosumab SC once Q6M in the double-blind phase. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.","id":"OG001","title":"Denosumab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set: all randomized participants","reportingStatus":"POSTED","timeFrame":"Randomization until end of main study, maximum duration of main study was 152 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Days"}